Skip to main content

Eulalia Gine Cipres

Institutions of which they are part

Main researcher
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Eulalia Gine Cipres

Institutions of which they are part

Main researcher
Headache and Neurological Pain
Vall Hebron Institut de Recerca

Projects

CHRONOS – Cronificación de la migraña: estudio longitudinal multi-ómico para la detección temprana, diagnóstico y prevención.

IP: Patricia Pozo Rosich
Collaborators: Laila Asskour , Eulalia Gine Cipres, Victor José Gallardo Lopez, Rut Mas deles Valls Cierco, Laura Gómez Dabó
Funding agency: Instituto de Salud Carlos III
Funding: 183750
Reference: PI25/01561
Duration: 01/01/2026 - 31/12/2028

MIGRANOSTIC: Estandardització d’un procediment diagnòstic molecular per a la migranya mitjançant biomarcadors de miARN

IP: Patricia Pozo Rosich
Collaborators: Laila Asskour , Eulalia Gine Cipres, Anna Cristina Segú Cristina, Victor José Gallardo Lopez, Edoardo Caronna
Funding agency: Generalitat de Catalunya - Departament de Salut
Funding: 64938.52
Reference: SLT041/25/000055
Duration: 04/12/2025 - 03/12/2026

Digitalización en la Educación de la Migraña

IP: Eulalia Gine Cipres
Collaborators: -
Funding agency: CONSEJO GRAL COLEGIOS OFICIALES ENFERMERÍA CGE
Funding:
Reference: CGE/PROYECTOS/GINE/2024
Duration: -

(PREDIMIGRAINE) Medicina de precisión para prevenir la cronificación de la migraña a través de la predicción de las crisis de dolor y de la respuesta al tratamiento con anticuerpos anti-CGRP utilizando estrategias multi-ómicas.

IP: Patricia Pozo Rosich
Collaborators: Alicia Alpuente Ruiz, Laila Asskour , Eulalia Gine Cipres, Victor José Gallardo Lopez, Nara Ikumi Montserrat, Edoardo Caronna
Funding agency: Instituto de Salud Carlos III
Funding: 369930
Reference: PMP22/00189
Duration: 01/01/2023 - 30/06/2026

Related news

On April 18 and 19, the Vall d’Hebron Research Institute (VHIR) will once again join the Science Festival 2026 with a diverse and participatory program focused on health, innovation, and citizen engagement in research.

The treatment with fremanezumab becomes the first approved therapy to demonstrate efficacy in children and adolescents, a key stage of life as it is one of the most disabling and concentrates the peak incidence of the disease.

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

Related professionals

Rut Román Freire

Rut Román Freire

Research assistant
Multidisciplinary Nursing Research Group
Read more
Dra. Anna Meseguer

Dra. Anna Meseguer

Read more
Sofia Alperi Garcia

Sofia Alperi Garcia

Predoctoral researcher
Childhood Cancer and Blood Disorders
Read more
Liubovi Sopco

Liubovi Sopco

Predoctoral researcher
Neurovascular Diseases
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.